ATOMO DIAGNOSTICS

FY26 RESULTS OVERVIEW

24 SEPTEMBER 2026

DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited ("Atomo") based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward-looking statements that are based on Atomo's beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

ATOMO DIAGNOSTICS - FY26 IN REVIEW

Transitioning to sustainable revenue growth with an expanding new product pipeline

Financial Highlights

- Revenue growth of **41%** bringing total revenue for the FY26 of **$5.3 million**
- EBITDA improvement of **39%** highlights increasing operating leverage in the business
- Cash receipts for the period totaling **$10.2 million**
  - *Cash on hand of $3.7 million on 30 June 2026 and the company remains debt free*
  - *$4.6m from customer receipts*
  - *$4.0m from capital raised during the period, net of transaction costs*

Business Highlights

- Strong growth in HIV franchise of **21%** to **$2.8 million**
- OEM revenue grew **209%** to **$2.2 million**, driven by Lumos Diagnostics launch of CLIA-waived FebriDx
- Onboarded Pharmacies in Australia selling the Atomo HIV Self-Test increases **56%** during the year plus July 2026 (**from 126 to 196** – more growth anticipated during FY27)
- Active syphilis technical product development completed, commencing with analytical and clinical studies in FY27
- Successful completion of Pascal orders received Jan 2026 for two new OEM customers – supports long-term supply agreements; anticipated early in FY27
- Commencing development efforts for ATL Liver function test - focus initially on liver function monitoring for patients prescribed at-risk drugs and fatty liver disease screening

NEW CHAPTER FOR ATOMO – FROM FOUNDATION TO GLOBAL SCALE

Passing the baton from founder leadership to the next phase of commercial growth

- **Building on 15 years of innovation and execution** under founder and long-standing CEO John Kelly
- **A seamless leadership transition** designed to preserve institutional knowledge while bringing global commercial focus
- **Dr. Cheri Walker appointed Interim CEO**, with extensive experience across life sciences, diagnostics and international commercialisation
- **Leadership positioned closer to Atomo's key growth markets**, particularly the US and Europe
- **Strategic priority shifts from foundation-building to scale:** accelerating adoption, expanding partnerships and maximising the value of Atomo's differentiated platform

atomo

REFLECTIONS ON FY26

FY26 established the foundation for Atomo's next phase of value creation

Accelerating growth: 41% FY26 revenue growth, reflecting strong momentum across the business

Improving economics: Continued improvement in EBITDA (+39% YOY) as scale, mix and operational discipline strengthen the underlying business

Capital discipline: Prudent cash management while maintaining the investment required for innovation and to support growth

Multiple growth engines: Increasing contribution from core HIV, OEM/Pascal and emerging product opportunities reduces reliance on any single revenue stream

Visible runway: Existing customer relationships, expanding distribution and new product launches provide a foundation for continued FY27+ growth

Pipeline creates future optionality: New products expand the addressable market and create additional platforms for future revenue

Long-term value creation: Building a **growing, diversified revenue base that can fund innovation and compound enterprise value over time**

WHO IS ATOMO AND WHAT DO WE DO?

Diagnostic company with a growing portfolio of patented rapid tests with proven superior usability, reliability, and performance

WHO IS ATOMO?

- We are a commercial stage diagnostic company with a growing revenue base from sales of approved professional and self-test point-of-care tests (POCT) across global markets
- Atomo solutions deliver unmatched usability and reliability that enable decentralised testing, a trend jump-started during the pandemic and now driven by global changes in rapid testing requirements and where timely centralized testing is not available
- Atomo is poised for significant growth with proven products in the market, a growing pipeline of products in development, and established partners launching exciting new POCT products across global markets

WHAT BUSINESSES DO WE HAVE?

Atomo Point of Care Test (POCT) Diagnostic Products:

- Blood-based rapid tests sold into professional use and self-test market channels on a global basis
- Focus on growing our pipeline of high value, reimbursed diagnostic products for decentralised professional testing

Point of Care Test Technologies (OEM Business):

- Growing partner sales driven by an FDA approved/CLIA waived test positioned for professional use, decentralised testing
- Integrated proprietary all-in-one device for partners seeking improved usability and performance for blood-based POCT
- Additional technologies that can integrate with the client's own cassette, turning it into a user-friendly system for blood-based POCT

ATOMO'S OWN DIAGNOSTIC PRODUCT PIPELINE

Commercial-stage diagnostic products company with a growing a portfolio of innovative point-of-care rapid tests for global markets

Product	Indication	Feasibility	Development	Validation	Clinical Trials	Regulatory Approvals					Commercial Launch					
						TGA	IVDR	MENA	USA	Other	AUS/NZ	EU/UK	Africa	USA	MENA	Other
Atomo																
Generation 3 HIV	HIV Detection - Self Test															
Generation 4 HIV	HIV Detection - Professional Use															
Generation 4 HIV	HIV Detection - Self Test															
Pregancy (HCG)	Professional/Self Test															
Active Syphilis	Active Syphilis Detection				3Q27											
Liver - ALT	Liver Disease Monitoring			2H27												
Hepatitis B- Virus (HBV)	HBV Detection															
Hepatitis C- Virus (HCV)	Professional															
Partner																
Lumos FebriDx™	Professional/CLIA-waived															
Chromacare Ferritin	Proffesional/Self Test															
Confidential UK Partner	Professional															

Complete
In Process

Pipeline focused on global professional use markets disseminating rapid testing to urgent care and other decentralised opportunities

PARTNER PORTFOLIO UPDATES

Expanding sales from attractive OEM business with products ranging from launched to new ones entering the pipeline

FebriDx Market Launch Continues

- Atomo partner Lumos Diagnostics received CLIA waiver of its FebriDx product, which uses Atomo's Pascal device for rapid, blood-based testing to differentiate bacterial versus non-bacterial infection. **US clinical trials validated greater than 99% concordance between trained and untrained users.** The target market includes urgent care and other reimbursed decentralised professional use testing.
- Atomo received FY26 orders for FebriDx totaling ~A$1.9 million, representing a nine-fold increase when compared to the prior year.

Ferritin – New Product Opportunity

- Atomo has partnered with Chromacare to develop a rapid test for measuring iron levels, with applications in both professional and at home self test markets. Initial order received this year from Chromacare worth ~A$170,000.

UK Customer

- Atomo is partnering with a UK company on a novel rapid test that addresses a large unmet clinical need in professional settings.
- In FY26, 20,000 Pascal units ordered to support validation and registration requirements. Commercial supply agreement for Pascal anticipated in early FY27.

FY26 – REVENUE SUMMARY

Strong sales growth across core activities in HIV Tests and Pascal OEM



Revenue growth across core activities

- HIV Growth **21%** YoY, totaling **$2.8 million**
- OEM Growth **209%** YoY, totaling **$2.2 million**
- Overall total revenue* growth **41%** YoY bringing total FY26 revenue to **$5.3 million**

* Total revenue includes development and other income

HIV BUSINESS ACTIVITY

Continued push on growing HIV sales is paying off in 21% YOY growth in HIV sales

Australian Pharmacy Growing Momentum

- **196 pharmacies active** in Australia
- **Target to grow 6x** over the next 3 years
- **59 new pharmacies added in FY26**

New Zealand – Expansion and foundation established

- **73 pharmacies activated** since launch in FY25
- **Target to grow 8x** over the next 3 years
- CDC (Pharmacy Wholesaler) commenced ordering towards end of FY26

Australia Government Program

- Rollover order from key government programs
- **NAPWHA demand has grown 275% over the last 24 months**

International HIV Business

Significant growth underway across European and LMIC markets



ACTIVE SYPHILIS – ADVANCING THROUGH THE PIPELINE

Successful completion of product development preparing for clinical trials in early CY27

Addressing significant unmet clinical and market needs

- **no existing rapid test can reliably distinguish active & prior infection**
- **no current test format is optimised for easy, reliable self-testing**

Established demand via existing HIV channels

Channel Leverage — Similar users, public buyers and distribution channels

Efficiency — Lower cost of entry, faster time to launch and scale revenue

Development & Commercial Readiness:

- **Product Development & Initial Verification Complete**

Strong product verification and preliminary clinical data supporting commercial interest
Sensitivity greater than 85% for active syphilis detection is market leading

- **Technology Transfer commenced for Manufacturing (Q4 FY26 and Q1 FY27)**

Enabling product for formal clinical trials and reg. submissions and validating manufacturing processes

- **Clinical Trials commencing early CY27**

Clinical validation planning underway and progressing toward commercialisation

- **Initial engagement with Regulator successfully completed**

Positive engagement with clinicians and key stakeholders to support market access

ALT LIVER TEST – ENTERS THE DEVELOPMENT PIPELINE

Unique, large product opportunity for detecting liver damage

01

Drug-Induced Liver Injury (DILI)

Monitoring for common drug types requiring ALT surveillance — TB drugs, Methotrexate, Leflunomide, Azathioprine, Valproate, Amiodarone, long-term Diclofenac.

Drug-Induced Liver Injury (DILI)

2025 SOM - A$72M
2032 SOM – A$100M

Commercial pathway: Confirming priority use case for clinical-trials and doctor prescribed at-home liver monitoring

Partner development: Engage with pharmaceutical, CRO or commercial partners during FY27

KOL engagement: Engagement commenced with clinical leaders in key channels – DILI / pharmaceutical conferences and Fatty Liver disease KOLs

03

Fatty Liver Disease Screening

High correlation between elevated ALT and fatty liver disease — affecting 1.5B+ people globally. Significant opportunity for home screening and monitoring of at-risk and diagnosed patients.

Fatty Liver Disease

2032 SOM – A$80M

Partner development: Engage with Australian clinical KOL's and public health to assess use of a screening test across high-risk cohorts for Fatty Liver disease

Assess funding opportunities for this application: Fatty Liver disease has a very large public health cost globally generating interest from governments

FEBRIDx – FY26 HIGHLIGHTS

2026 and future revenue growth driven by Lumos Diagnostics CLIA waiver, sales focus, and distribution partnership

- **Atomo received FY26 orders for FebriDx totaling ~A$1.9m,** representing a nine-fold increase in Pascal FebriDx orders when compared to FY25
- **Lumos signed a six-year agreement with PHASE Scientific** for supply of FebriDx® in US **-** Lumos anticipates FebriDx product revenues of up to US$317 million over the term, assuming CLIA waiver is granted and contracted MOQ's achieved
- **FebriDx® received CLIA waiver from the US FDA, based on Pascal performance -** validated in US trials as delivering greater than 99% concordance between trained and untrained users
- **Each FebriDx® test sold to Phase requires Lumos order a Pascal cassette**, with Atomo receiving a percentage portion of the proceeds based on the transfer price of Pascal



CHROMACARE – FERRITIN OPPORTUNITY

Another high value product targeted to the professional use, decentralised testing market

Rapid Test to screen for Iron Deficiency in Point-of-Care

Other Tests in active development

- Atomo has partnered with Canadian company Chromacare on a rapid test that can measure iron levels (Ferritin), with applications in both professional and at home self test markets. Initial order received this quarter from Chromacare worth ~A$170,000
- Pascal units supplied to support product validation and registrations – long term commercial supply agreement for Pascal anticipated in early FY27
- Chromacare interest in a US CLIA waiver submission supported by Pascal and utilising Pascal FebriDx as a predicate



UK CLIENT – EXCITING NEW POCT PRODUCT CATEGORY

Successful completion of manufacture of products for feasibility study

UK Customer

- Atomo is partnering with a UK company on a novel rapid test that addresses a large unmet clinical need in professional settings
- 20,000 Pascal units ordered to support validation and registration requirements. Commercial supply agreement for Pascal anticipated in early FY27

Promotion post CLIA waiver

- Atomo is implementing market engagement and partnering with a number of US test development companies on promotion of Pascal as a proven solution for rapid blood test assays seeking expanded market access through CLIA waiver approval in the US* or launching as a self test



** CLIA waiver approval typically increases the addressable market for a rapid blood test >10-fold*
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02979439-2A1614136&v=4a466cc3f899e00730cfbfcd5ab8940c41f474b6

FY26 OPERATIONAL UPDATE

Execution on important steps to increase resilient capacity and improve gross margins

Operational expansion initiated to support the growth of Atomo Diagnostic Products and OEM Pascal units

- Increased production capacity and improved margins on supply of Pascal to customers and for use in Atomo finished diagnostic tests
    - Qualification underway of high cavitation injection mould tooling to increase component capacity and reduce Cost of Goods (COGs)
    - Qualification of the company's proprietary high volume Blister Machine #2 – now located in an Atomo operated facility in Sydney
- Expansion of Finished Test Assembly / Packaging accreditation at Atomo's South Africa beyond HIV to include supply of Active Syphilis tests
- **Blister Machine 2** was successfully relocated to an Atomo-operated facility in Sydney. The facility will be integrated into Atomo's Quality Management System (QMS) in the coming months



STRATEGIC INITIATIVES in FY27 AND BEYOND

Establish Atomo as a growing diagnostic company with a robust product pipeline

Increasing Focus on New Atomo Products: Successfully finish development and launch Active Syphilis and Liver ALT marker while completing feasibility on additional pipeline products including Gen4 HIV and evaluating HBV, HCV and other tests to complement the POCT, professional use portfolio.

Expand Partnership Activity on a Global Basis: Add more development partners to take Pascal platform into more indications; support current OEM partners, identify commercial partners for Atomo products in the US and other markets.

Increase Manufacturing Capacity, Capabilities and Efficiency: Complete current and future projects to increase capacity and platform functionality while reducing manufacturing costs with a focus on additional operating leverage and increased profitability.

Commercial Execution and Expansion: Grow the markets and sales for current HIV and pregnancy products, sign additional development partners, build a sales and marketing platform with maximum impact, and develop commercial launch and partnering activities for active syphilis, liver ALT, and other Atomo products.

Long-Term Value Creation: Build a growing, diversified revenue base that can fund innovation and compound enterprise value which will lead to increased market capitalization and stock price appreciation.

FY 2026 FINANCIALS

FY26 PROFIT & LOSS

Strong revenue growth and improving EBITDA while investing in innovative R&D development and pipeline

AUD	FY26 ($m)	FY25 ($m)	(%)
Revenue	5.33	3.79	41%
Cost of sales	(3.45)	(1.87)	
Gross Profit	**1.88**	**1.92**	**(2%)**
Gross Margin	**35%**	**51%**	
Other income	2.24	1.52	47%
Employee benefits expense	(2.88)	(3.26)	12%
Foreign exchanges gains/(losses)	(0.04)	(0.01)	(300%)
Research and development costs	(0.76)	(0.62)	(23%)
Professional fees expense	(0.49)	(0.95)	48%
Inventory obsolescence expense	(0.12)	(0.13)	8%
Other expenses	(1.89)	(1.85)	(2%)
Underlying EBITDA	**(2.06)**	**(3.38)**	**39%**

- **Revenue up 41%,** driven by strong volume demand across HIV Global Health Market
- **Gross margin lower** due to product mix
  - Prior including net ~$340k in one-off license fees, impacting margin by 6% YoY
  - Core product margin excluding licence and developments fees was 35% vs 42% YoY.
  - Shift driven by higher product demand from lower yielding Global Health market segments
- **Operational discipline** with overall expense reducing YoY $640k/+9%.
- **Investment in R&D activities** further offset eligible operational costs during the period. Net improvement of $1.34m/+25% YoY.
- **Underlying EBITDA improved 39%** from a loss of $3.38m to a loss of $2.06m, representing a meaningful step towards profitability

FY26 BALANCE SHEET

Finishing the year with a solid cash position and no debt

AUD	FY26 ($m)	FY25 ($m)
Cash and cash equivalents	3.71	3.22
Trade and other receivables	3.22	1.69
Inventories	1.97	1.65
Property, plant and equipment	0.34	0.89
Intangible assets	1.22	1.64
Other assets	0.36	0.18
Total assets	**10.82**	**9.27**
Trade and other payables	1.68	1.02
Other liabilities	1.43	1.28
Total liabilities	**3.11**	**2.30**
Net Assets	**7.71**	**6.97**

- **Cash and cash equivalents of $3.71m at 30 June 2026,** and remaining debt free
- During the year, the Atomo completed **capital raisings of $4.0m net of transaction costs,** provide funding to support ongoing commercialisation, product development and funding future growth initiatives.
- Capitalised expenditure relating to R&D and PPE for the period was not significant
- Atomo's balance sheet supports ongoing investment in portfolio expansion, pipeline development opportunities and cost of goods reduction initiatives, aimed at driving future revenue growth and improving margins.

FY26 CASHFLOW

Strong cash generation from sales, grants, and fundraising activities



- **Total Cash receipts: $10.2m**
  - ~$4.6m from customer receipts
  - $875k from R&D tax rebate
  - $660k from CRC-P grant for Syphilis test development
  - ~4m from capital raised during the period, net of transaction costs
- **Total Cash payments: $9.7m**
  - $4.1m in stock purchases
  - $5.6m in operating expenses
- **Year-end cash balance of $3.7m, no debt**

FINANCIAL SUMMARY

FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA

- ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Testing and Pascal OEM
- ✓ Expansion of customer base across new partners for Pascal and an expanded Atomo test product pipeline



- ✓ Capital focus on new test portfolio development / commercialisation – Syphilis and Liver
- ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support lower-cost development and go to market
- ✓ EBITDA – continued trend towards breakeven as existing revenue channels grow and product offerings expand

- ✓ **Debt free balance sheet**
- ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale and margins



FY26: YEAR OF TRANSITION

Building a platform for sustainable growth

Strong revenue momentum: FY26 revenue growth of **41%**, demonstrates increasing demand across Atomo's core business lines and emerging opportunities

Improving operating leverage: EBITDA performance continued to improve as revenue growth increasingly flows through the business

A business increasingly positioned for scale: Revenue growth is becoming broader-based, with momentum across HIV, OEM/Pascal and emerging diagnostic opportunities

Confidence in sustainable growth: We expect the underlying revenue trajectory to continue into **FY27 and beyond**, supported by multiple complementary growth engines

Reinvesting growth into innovation: As revenue increases, it is expected to cover most non-research operating costs, providing the opportunity to selectively reinvest in **R&D and product development** for an attractive future return on investment

Expanding the product pipeline: Investment in new tests and applications can broaden Atomo's addressable markets and create additional exciting and significant commercial opportunities

Creating a compounding value proposition: Revenue growth → improved operating leverage → reinvestment in R&D → broader product portfolio → longer-term revenue growth and enterprise value

Atomo Strategy Update and FY26 Full Year Investor Webinar Presentation

Atomo Diagnostics Limited will hold its Strategy Update and FY26 Full Year Investor webinar on Thursday 24th September 2026 at 11:00 AM.

To access Atomo's Investor Hub please scan the QR code.

For further information, please contact:

Cheri Walker, Interim CEO and Executive Director
Cheri.Walker@atomodiagnostics.com
p. +61 2 9099 4750

Investor Queries investor
Investorqueries@atomodiagnostics.com